LABT (Lakewood-Amedex Biotherapeutics) Inventories, Inventories Adjustments: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LABT Lakewood-Amedex Biotherapeutics Inc LABT
8 GF Score
Price $2.37
View Full Analysis

What is Lakewood-Amedex Biotherapeutics Inventories, Inventories Adjustments?

Lakewood-Amedex Biotherapeutics LABT 8 Inventories, Inventories Adjustments is $0.00 Mil as of Mar. 2026. GuruFocus rates LABT with a GF Score™ of 8/100.

Lakewood-Amedex Biotherapeutics's Inventories, Inventories Adjustments for the quarter that ended in Mar. 2026 was $0.00 Mil.

Lakewood-Amedex Biotherapeutics Inventories, Inventories Adjustments Historical Data

* Premium members only.

The historical data trend for Lakewood-Amedex Biotherapeutics's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakewood-Amedex Biotherapeutics Inventories, Inventories Adjustments Chart

Lakewood-Amedex Biotherapeutics Annual Data
Trend Dec23 Dec24 Dec25
Inventories, Inventories Adjustments
0.00 0.00 0.00

Lakewood-Amedex Biotherapeutics Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Inventories, Inventories Adjustments Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
LABT
8GF Score
Lakewood-Amedex Biotherapeutics Inc LABT
Inventories, Inventories Adjustments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakewood-Amedex Biotherapeutics Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.

What does a Inventories, Inventories Adjustments of $0.00 Mil mean?
Lakewood-Amedex Biotherapeutics (LABT) has a Inventories, Inventories Adjustments of $0.00 Mil as of Mar. 2026. Inventories, Inventories Adjustments is certain charges made in the current period in inventory resulting from breakage, spoilage, etc. View historical data on Lakewood-Amedex Biotherapeutics and its competitors.
Is Lakewood-Amedex Biotherapeutics' Inventories, Inventories Adjustments too high?
Lakewood-Amedex Biotherapeutics' current Inventories, Inventories Adjustments is $0.00 Mil. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' Inventories, Inventories Adjustments compare to CDIO and JAGX?
Lakewood-Amedex Biotherapeutics' Inventories, Inventories Adjustments of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Inventories Adjustments for a Biotechnology company?
A good Inventories, Inventories Adjustments depends on the Biotechnology industry context. However, Inventories, Inventories Adjustments should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Inventories Adjustments mean?
A high Inventories, Inventories Adjustments can signal that a stock is expensive relative to its fundamentals. Inventories, Inventories Adjustments is certain charges made in the current period in inventory resulting from breakage, spoilage, etc. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. Lakewood-Amedex Biotherapeutics's current Inventories, Inventories Adjustments is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current Inventories, Inventories Adjustments of $0.00 Mil. The current Inventories, Inventories Adjustments is $0.00 Mil. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Inventories Adjustments calculated?
Inventories, Inventories Adjustments is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current Inventories, Inventories Adjustments is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lakewood-Amedex Biotherapeutics Business Description

Address 8031 Cooper Creek Blvd, Unit 103, University Park, FL, USA, 34201
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score

Get the complete analysis for LABT

Inventories, Inventories Adjustments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.37
Price